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Abstract
CD44 is commonly used as a cell surface marker of cancer stem-like cells in epithelial tumours, and we have previously
demonstrated the existence of two different CD44high cancer stem-like cell populations in squamous cell carcinoma, one
having undergone epithelial-to-mesenchymal transition and the other maintaining an epithelial phenotype. Alternative
splicing of CD44 variant exons generates a great many isoforms, and it is not known which isoforms are expressed on the
surface of the two different cancer stem-like cell phenotypes. Here, we demonstrate that cancer stem-like cells with an
epithelial phenotype predominantly express isoforms containing the variant exons, whereas the cancer stem-like cells that
have undergone an epithelial-to-mesenchymal transition down-regulate these variant isoforms and up-regulate expression
of the standard CD44 isoform that contains no variant exons. In addition, we find that enzymatic treatments used to
dissociate cells from tissue culture or fresh tumour specimens cause destruction of variant CD44 isoforms at the cell surface
whereas expression of the standard CD44 isoform is preserved. This results in enrichment within the CD44high population of
cancer stem-like cells that have undergone an epithelial-to-mesenchymal transition and depletion from the CD44high
population of cancer stem-like cells that maintain an epithelial phenotype, and therefore greatly effects the characteristics
of any cancer stem-like cell population isolated based on expression of CD44. As well as effecting the CD44high population,
enzymatic treatment also reduces the percentage of the total epithelial cancer cell population staining CD44-positive, with
potential implications for studies that aim to use CD44-positive staining as a prognostic indicator. Analyses of the properties
of cancer stem-like cells are largely dependent on the ability to accurately identify and assay these populations. It is
therefore critical that consideration be given to use of multiple cancer stem-like cell markers and suitable procedures for cell
isolation in order that the correct populations are assayed.
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Introduction
Cancer stem-like cells (CSCs) are defined as a subpopulation of
tumour cells that have both tumour-initiating ability and the
ability to reconstitute the cellular heterogeneity typical of their
tumours of origin [1]. Cells with such properties have been found
in cancers arising in haematopoietic, epithelial, neural and other
tissues [2–5]. Marked clinical interest in CSCs has arisen due to
reports of unique CSC properties that implicate them in local
tumour invasion, metastasis, and therapeutic resistance [6–9].
Although initially CSCs were thought typically to represent a
relatively small fraction of the total number of tumour cells,
subsequent reports suggest that their number may vary quite
widely both within a given type of tumour and between differing
types of tumours [10,11]. Such differences in the size of the CSC
fraction within tumours is reported to be of prognostic significance
[12,13] but the accuracy of methods currently used to determine
the proportion of cells with CSC properties is uncertain.
CSCs are typically identified by their higher levels of expression
of certain cell surface molecules but other characteristics, such as
greater expression of ABC transporters and of molecules such as
Aldh1, have also been used to isolate cells with CSC characteristics
[14,15]. The tumour initiating properties of cell fractions is
typically assessed by murine transplantation and this has been
taken as the ‘‘gold standard’’ functional assay [1]. However, the
fraction of cells found to initiate tumours on transplantation is
influenced markedly not only by the method and site of
transplantation but also by the type of recipient mouse [10]. In
addition, it is unclear how the composition of test populations is
influenced by the method used for their isolation, and there has
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been little investigation of the effects of differing methods of cell
isolation on the levels of CSC markers subsequently detectable. In
particular, many cell isolation protocols use the proteolytic
enzymes trypsin [10,16] and collagenase [3,12,15], yet it is not
known whether these enzymes degrade cell surface molecules used
to isolate CSCs.
For tumours of epithelial origin, including those of the head and
neck, breast, prostate and colon, isolation of CSCs has frequently
been based on their greater cell-surface expression of CD44
[2,3,17–19]. CD44 is a multifunctional and ubiquitously expressed
glyco-protein adhesion molecule derived from a gene with 18
exons, 9 of which are expressed in the standard form. Alternative
splicing of the remainder generates a great many variant (CD44v)
isoforms [20]. CD44 expression potentially influences stem cell
behaviour by a wide range of mechanisms [21] and interaction
with hyaluronan, its principal ligand, influences several signalling
pathways [20,22] and initiates signalling functions associated with
nuclear translocation [23]. The abrogation of tumour growth
resulting from CD44 inhibition, either in vivo or in vitro, indicates its
functional significance [24,25] and differential patterns of expres-
sion of CD44 isoforms can similarly affect cellular properties [26].
Epithelial-to-mesenchymal transition (EMT), first described as a
developmental process during which epithelial cells acquire a
motile mesenchymal phenotype [27], has since been shown to play
an important role in the invasion of cancers of the head and neck,
breast and several other tissues [28,29]. In addition to its roles in
motility, EMT has been implicated in the development of
therapeutic resistance and tumour recurrence [7,29–31]. Recently,
we demonstrated that the CD44high CSC fraction in cell lines
derived from head and neck and cutaneous squamous cell
carcinoma (SCC) exists in at least two phenotypic forms that
differ in their patterns of cell surface marker expression and their
ability to survive in suspension [32]. Although both CSC
phenotypes are characterized by high levels of expression of
CD44, they are distinguished by different levels of expression of
epithelial-specific-antigen (ESA). CSCs with a CD44highESAhigh
expression pattern have an epithelial phenotype and are prolifer-
ative, whereas CD44highESAlow cells are CSCs that have
undergone EMT and are motile. CSCs can switch between these
two phenotypes through the processes of EMT and mesenchymal-
to-epithelial transition (MET). Expression of EMT markers at the
invasive front of colon and oral carcinoma [33,34], correlation of
EMT marker expression with tumour aggression [28], and
isolation of cells expressing EMT markers from fresh tumour
samples [35], indicate the in vivo occurrence of EMT as a
mechanism associated with the spread of tumours.
We have examined whether the two different CSC phenotypes
in SCC exhibit differential CD44 isoform expression. A further
point of interest was that varying proteolytic sensitivities of CD44
epitopes [36] could result in differential sensitivity of the CD44
isoforms to proteolytic enzymes used for cell dissociation and thus
different cellular populations being identified as CD44high
depending on the cell dissociation method used. We therefore
investigated how the method of cell isolation from intact tumours,
or release from culture, can influence their surface retention of
different CD44 isoforms and, consequently, the properties of the
cell fraction detected as CD44high CSCs. We show that the motile
CD44highESAlow CSCs have higher expression of the standard
CD44 isoform but lower expression of CD44v isoforms. Further,
the standard CD44 isoform is less sensitive to enzymatic treatment
than CD44v isoforms and this can greatly influence the relative
degree of CD44 staining detected on ESAhigh versus ESAlow CSCs,
depending on the method of cell dissociation used. Comparison of
various methods of cell dissociation, both from cell lines and from
fresh tumours, demonstrates that they result in different popula-
tions of cells being identified as CD44high.
Materials and Methods
Cell culture
The CA1 cell line was previously derived in our laboratory from
a biopsy of oral SCC of the floor of the mouth [37]. The Met1 and
Met2 cell lines were derived within our Centre from matched
malignant cutaneous SCC tissues [38]. All cell lines were grown in
a highly supplemented epithelial growth medium (termed FAD)
with 10% FBS [39].
FACS
For FACS analyses, cells were detached from cultures at 37uC
using either 16 trypsin-EDTA (PAA, #L11-004), Accutase (PAA,
#L11-007) a widely used commercial product that combines
protease and collagenolytic activities, or enzyme-free cell dissoci-
ation buffer (Invitrogen, #13151-014). The length of dissociation
varied between these buffers, and was determined by observing the
time taken for complete dissociation of the cells from the dish.
Typically, trypsin required 5–10 minutes dissociation, Accutase
10–15 minutes and Enzyme Free buffer 30 minutes. One million
cells per ml were then stained with antibodies at 1:100 dilution in
PBS (PAA) for 15 minutes. The DAPI nuclear dye (Sigma) was
used at 1 ug/ml to exclude dead cells. The antibodies used were as
follows; PE-CD44 (clone G44–26) and PE-Integrin b4 (clone 439-
9B) were from BD biosciences; APC-ESA (clone HEA-125) was
from Miltenyi Biotec; PE-CD44v3 (clone 3G5) was from R&D
systems; CD44v4 (clone VFF11), CD44v9 (clone FW11.24) and
FITC-CD44v6 (clone VFF7) were from Bender Medsystems;
CD44v5 (clone VFF8), FITC-CD44v7/8 (clone VFF17) and
CD44v10 (clone VFF14) were from AbD Serotec; the FITC
rabbit-anti-mouse secondary antibody was from Invitrogen. The
FITC- and PE- conjugated mouse IgG isotype control antibodies
were from BD. Biosciences. Populations of FACS sorted cells were
collected into buffer RLT (Qiagen) for RNA extraction.
RNA extraction, cDNA synthesis and QPCR
RNA was extracted from 50000 FACS sorted cells using the
RNeasy micro kit (Qiagen). Reverse transcription into cDNA was
conducted using the Superscript III first strand synthesis supermix
(Invitrogen), with inclusion of –RT controls. QPCR was conduct-
ed in an ABI 7500 real-time PCR system (Applied Biosystems)
using Power SYBR green mix (Applied Biosystems). GAPDH was
used as a reference mRNA control. QPCR cycling conditions
were: 95uC for 10 mins, [95uC for 15 seconds, 60uC for
30 seconds, 72uC for 40 seconds] (40 cycles), 95uC for 60 seconds,
followed by dissociation curve analysis. Reverse transcribed
Human Total Reference RNA (Stratagene) was used to generate
a standard curve. The primer sequences used are shown in
Appendix S1 and the QPCR Ct-plots are shown in Appendix S2.
Extraction and staining of cells from primary tumours
For analysis of cells isolated from fresh tumours, small pieces of
oral SCC that were surplus to diagnostic requirements were
collected, with informed consent and without patient identifiers
following protocols approved by the local NHS Research Ethics
Committee., and transported to the laboratory in ice-cold FAD
medium. Tissues were chopped into small pieces, approximately
161 mm, washed in medium, and spun down. Cell suspensions
were isolated using a Seward Stomacher 80 (Biomaster), an
apparatus that dissociates tissues by intermittent squeezing. Each
tumour sample was aliquoted into 3 individual Stomacher bags
CD44 Staining of Cancer Stem Cells
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e57314
Figure 1. CD44 standard and variant exons. A representation of the 9 standard and 9 variant exons of CD44, showing the names of each variant
exon and where they fall in the extracellular region of the protein product. The position of the ‘‘Epitope 1’’ region recognised by the CD44 antibody
used in these studies is indicated.
doi:10.1371/journal.pone.0057314.g001
Figure 2. CD44 expression in EMT and non-EMT CSCs. (A) FACS sorting of CA1, Met1 and Met2 cells by expression of CD44 (using the ‘‘epitope
1’’ antibody that detects all forms of CD44) and ESA. The CD44highESAlow and CD44highESAhigh sub-populations are gated and show higher levels of
staining of CD44highESAlow cells for CD44. (B) QPCR analysis of CD44 variant gene expression in CD44highESAlow cells relative to the CD44highESAhigh
cells for the CA1, Met1 and Met2 lines shows marked differences in the isoform expression patterns.
doi:10.1371/journal.pone.0057314.g002
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containing either FAD medium, 16 trypsin-EDTA (PAA, #L11-
004), or 2.5 mg/ml Collagenase III (Sigma, #C0255). Bags were
placed into the apparatus and pulsed at low speed for a total of
45 min. with medium withdrawn from the bags and replaced with
fresh medium each 15 min. Cells in the fluids collected at the 3
time periods were pooled, and spun down. As only small tissue
specimens were available, the number of cells obtained was too
low to permit FACS analysis. The cell pellets were therefore
resuspended in 0.1 ml FCS, and prepared as cell smears on
polysine coated slides (VWR). Slides were air dried and fixed in
ice-cold acetone/methanol (50:50) and co-stained with DAPI to
define nuclei, with rabbit anti-human keratin antibody (AbD
Serotec) to identify epithelial cells, and with antibodies as listed
above against CD44s and several variant isoforms (1:100 dilution).
For each of 5 separate tumours, 4 or more random fields
containing 150–300 cells were photographed using filter sets
distinguishing cell staining for DAPI, keratin, and CD44. Images
captured at standardized exposures were imported into PhotoShop
(Adobe) and, using the Wand tool adjusted to a level of tolerance
that captured visually stained cells, secondary images of isolated
stained cells were generated for each fluorochrome. The 3 images
of each field were then combined, slightly out of lateral register, to
Figure 3. Trypsin treatment prevents cell surface detection of CD44 variant isoforms. Histograms showing expression, assessed by FACS
analyses of CA1 cells, of CD44 (‘‘epitope 1’’ antibody, top left panel) and of CD44 variants after treatment with trypsin (green) or enzyme-free buffer
(blue). The isotype control is in red.
doi:10.1371/journal.pone.0057314.g003
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identify the presence or absence of staining for keratin and CD44
associated with each DAPI stained nucleus. Counts were made of
total number of cell nuclei, of cells unstained for keratin or CD44,
and of cells stained for CD44 alone, for keratin alone, or for both
CD44 and keratin.
Statistical analysis
All data are based on at least three experimental repeats, unless
otherwise stated, and are reported as mean 6SEM. P-values were
obtained using a Mann-Whitney U test.
Results
CD44highESAlow EMT CSCs express higher levels of the
standard CD44 isoform and lower levels of variant CD44
exons, compared with the CD44highESAhigh epithelial
CSCs
In previous studies, cells with CSC properties have been
distinguished from the non-CSC population primarily by their
higher levels of CD44 expression. However, the gene coding for
the CD44 glycoprotein contains 9 standard and 9 variant exons
that generate multiple isoforms (24) (Figure 1). As these influence
cell behaviour, it was of interest initially to determine whether
differences in isoform expression patterns exist between the EMT
(CD44highESAlow) and non-EMT (CD44highESAhigh) CSC sub-
populations that we have previously identified in SCC [32]. The
CD44 antibody used in this study and in our previous study [32]
binds ‘‘epitope 1’’ present in the distal region of all CD44 isoforms
(Figure 1). It therefore recognizes not only the ‘‘standard’’ CD44
isoform, which lacks variant exons, but all other variant CD44
isoforms (CD44v). These include the CD44 ‘‘total’’ isoform, which
contains all variant exons, the CD44 ‘‘epithelial’’ isoform, which
contains the v8, v9 and v10 variant exons, and other CD44
molecules containing other combinations of variant exons [40,41].
This antibody was used in combination with an antibody against
ESA for an initial flow-cytometric analysis of the CA1, Met1 and
Met2 cell lines. Cells brought into suspension using a standard
trypsin-EDTA method (PAA) showed higher staining for CD44 of
CD44highESAlow cell fractions compared to CD44highESAhigh cells
(Figure 2A). It was therefore surprising that QPCR primers that
detect all forms of CD44 indicated little difference in the total
CD44 mRNA levels between these populations (Figure 2B).
However, when CD44 expression was analysed using PCR
primers that detect differences in variant isoform expression, it
was consistently found that CD44highESAlow cells had relatively
higher expression of the standard CD44 isoform but lower
expression of the CD44 total isoform, the CD44 epithelial isoform,
and of individual variant exons v3, v4, v6, v8 and v10.
Figure 4. Detection of CD44 variant isoform expression on the CD44highESAhigh cell sub-population. FACS analysis of CD44 variant
isoform expression on cells of the CA1 (A), Met1 (B) and Met2 (C) cell lines isolated using enzyme-free buffer showing the CD44 variants on the y-axis
and ESA expression on the x-axis. For all cell lines, similar total levels of CD44 are detected on the CD44highESAlow and CD44highESAhigh cells but lower
levels of the v3, v5, v6 and v9 isoforms are detected on the CD44highESAlow cells. (D) FACS analysis of CD44 (y-axis) and ESA (x-axis) expression on CA1
(top), Met1 (middle) and Met2 (bottom) cells treated with either trypsin (left) or enzyme-free buffer (right). Loss of detection of CD44 variant isoforms
after trypsin treatment results in a large increase in the fraction of motile CSCs within the 5% of cells showing the highest CD44 expression.
Representative plots. (E) Quantification of the experiments depicted in figure 4D, showing the percentage of EMT CSCs within the 5% CD44high
population after treatment with trypsin or enzyme-free buffer.
doi:10.1371/journal.pone.0057314.g004
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Enzyme treatment reduces detection of CD44 variant
isoforms
As trypsin treatment has been reported to destroy some CD44
cell surface epitopes [36], we examined what effects various cell
dissociation methods used to bring cells into suspension have on
CD44 staining patterns subsequently detected by flow cytometry.
CA1 cells were released from adherent culture using trypsin or
enzyme-free buffer and then stained with the ‘‘epitope 1’’ antibody
or antibodies against several individual CD44 variants (Figure 3
and Appendix S3). Epitopes encoded by v4, v7/8 and v10 were
never detected but those encoded by v3, v5, v6 and v9 were
strongly detected on cells released with enzyme-free buffer whereas
only very little signal was detected on cells released with trypsin,
indicating sensitivity of the variant isoforms to trypsin.
CA1, Met1 and Met2 cells released with enzyme-free buffer and
co-stained for CD44 variants and ESA (Figure 4 A, B and C)
confirmed that the CD44highESAlow cells express lower levels of
the v3, v5, v6 and v9 variant proteins. When variant CD44
isoforms were conserved, CD44highESAlow cells were not in fact
much higher than the bulk population of cells for CD44 staining
(Figure 4D). Further, it can be seen that if the top 5% of cells are
selected based on CD44 staining alone, the composition of this
CD44high population changes markedly depending on which
isolation method is used, with a much higher proportion of the
population being comprised of EMT CSCs if enzymatic isolation
is used. Thus it is the stability of the standard CD44 isoform and
its increased expression on the CD44highESAlow EMT CSCs that
results in enrichment of these cells within the CD44high population
after enzymatic isolation with trypsin.
To visualise the effect of different cell dissociation methods on
the percentage of cells reported as CD44-positive in flow
cytometry, we dissociated the CA1 cell line from culture using
either trypsin, enzyme-free buffer, or Accutase (a proprietary
enzymatic solution claimed by the manufacturer to have less
general proteolytic activity than trypsin) and then stained for
CD44 (Figure 5 and Appendix S3). The different isolation
methods had no effect on isotype control staining, but there was
a marked difference in the proportion of cells staining CD44-
positive using the different methods. The enzymatic destruction of
Figure 5. Enzyme treatment decreases the size of the CD44-positive population. Following isolation with trypsin, Accutase or enzyme-free
(EF) buffer, CA1 cells were subject to FACS analysis either unstained, stained with an isotype control, or stained for CD44. Unstained and isotype-
stained cells were unaffected by method of isolation but marked differences in the proportion of cells classified as staining positive for CD44 are seen.
doi:10.1371/journal.pone.0057314.g005
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CD44 variants therefore has a profound effect on the percentage
of cells that are reported as CD44-positive in analysis of cells after
enzymatic dissociation.
Enzymatic dissociation reduces detection of CD44-
positive cells in fresh tumour specimens
The staining of CD44 expressing cells in cell populations
isolated from fresh biopsies of head and neck SCC also varied with
the method of isolation. As shown in Figure 6, cell smears were co-
stained with DAPI, a pan-keratin antibody, and the CD44
‘‘epitope 1’’ antibody. This enabled counts of cell nuclei and
classification of cells as stained or unstained for CD44. The keratin
antibody was used to mark epithelial cells. We compared two
commonly used enzymatic isolation methods, trypsin plus
collagenase [10,16] and collagenase alone [3,12,15], with extrac-
tion without enzymes. Cell counts indicated variation in the size of
both the fraction of the total cells classified as positive for CD44
and in the size of the cell fraction positive for both CD44 and
keratin (Fig. 6 E,F). Staining for CD44 indicated that the stained
fraction of cells was significantly higher after extraction without
enzymes than after extraction with trypsin plus collagenase (CD44
positive: Mann–Whitney U=0, n1 = n2 = 5, P,0.01 two-tailed;
CD44 positive+Keratin positive: Mann–Whitney U=2,
n1 = n2 = 5, P,0.05 two-tailed). Staining was also somewhat
reduced by extraction with collagenase alone, although this was
not statistically significant. As has been noted previously [12], we
also witnessed a large variation in the percentage of CD44-positive
cells between tumours (Fig. 6G). However, treatment with trypsin
plus collagenase or collagenase alone consistently caused a
decrease in the percentage of cells stained CD44-positive across
all tumours and also caused a decrease in the variation in CD44
staining between tumours.
Discussion
Previous reports concerning isolation of CSCs from tumours
and tumour cell lines have described the use of a range of stem-
cell-related markers but expression of CD44, alone or together
with additional markers, has been widely used for the identifica-
tion of CSCs in breast, oral, prostate, colon and pancreatic
malignancies [2,3,17–19]. The CD44 antibody employed in the
present and most previous studies of CSCs [2,3,18,32,35]
recognizes all CD44 isoforms and consequently does not indicate
how total levels are influenced by variation in patterns of isoform
expression. In the present study we found, using flow cytometry,
that the total levels of CD44 expression detected for cells isolated
Figure 6. Differential staining for CD44 on cells isolated from fresh tumour samples using different methods. Panels A–D illustrate the
procedure used to identify staining patterns. Cell smears were prepared and co-stained with DAPI (A) with a pan-keratin antibody (B) and with the
CD44 ‘‘epitope 1’’ antibody (C). These panels show images manipulated by adjusting capture thresholds in PhotoShop to identify cells with set levels
of staining above a background level. For each field, this level was held constant to generate the three images, one for each fluorochrome, containing
only the stained cells. These images were then combined, slightly out of lateral register, to allow identification of cells with absent or low levels
staining for CD44 or keratin (blue nuclei only), staining for CD44 only (CD44+), keratin only (K+), or both CD44 and keratin (CD44+K+). Treatment with
trypsin+collagenase or collagenase alone consistently reduced the fraction of cells that was positive for CD44 (E) and for both CD44 and keratin (F).
Displaying the 5 assayed tumours individually (G) demonstrates the striking variation in CD44 staining between tumours, and that this variation is
reduced following enzymatic treatment. Statistical analysis was conducted using a Mann-Whitney test.
doi:10.1371/journal.pone.0057314.g006
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by non-enzymatic methods were similar for EMT and non-EMT
cells. However, the pattern of isoform expression differed with the
standard CD44 isoform being more highly expressed by the EMT
CSCs and variant CD44 isoforms more highly expressed by the
non-EMT CSCs. Cell dissociation using trypsin reduced the CD44
staining of the non-EMT CSCs, with a consequent enrichment for
EMT CSCs in the CD44high/+ population. This is due to the
greater proteolytic sensitivity of the variant CD44 isoforms, which
are destroyed by trypsin treatment whilst the standard CD44
isoform is preserved. The same effect was demonstrated during cell
isolation from fresh tumour specimens, in which commonly used
methods of enzymatic cell dissociation caused a reduction in cell
staining for CD44 when compared with a non-enzymatic
dissociation method.
The reduction in CD44 staining resulting from treatment with
proteolytic enzymes caused a reduction both in the representation
of epithelial CSCs within the CD44high population and the
percentage of the total epithelial cancer cell population staining
CD44-positive. Previously, some studies using CD44 as a CSC
marker have concentrated only on the CD44high population
[2,32,35] whereas others have isolated the entire CD44-positive
population from tumours [3,12]. Our results show that the method
of cell dissociation will effect the composition of the isolated cell
population in both types of study. The observed reduction, and
reduced variation between tumours, of CD44-positive staining
after enzymatic dissociation may be of particular significance for
studies that aim to use CD44-positive staining as a prognostic
indicator [12].
Analyses of the properties of CSCs are largely dependent on the
ability to accurately identify and assay them. We have previously
demonstrated the existence of two different CD44high CSCs in
SCC, one a fast-growing non-EMT CSC with an epithelial
phenotype and the other an invasive EMT CSC with a
mesenchymal phenotype [32]. The demonstration that the two
different CSC sub-populations express CD44 isoforms that are
differentially affected by isolation procedures, resulting in varying
levels of enrichment of the two CSC types within the CD44high
fraction, has implications for studies involving isolation or
characterization of CSCs based on their expression of CD44.
EMT and non-EMT CSCs exhibit very different behaviour both
in vitro and in vivo [32]. It is therefore critical that consideration be
given to use of multiple CSC markers and suitable procedures for
cell isolation in order that the correct populations are assayed in
studies of CSCs.
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